Insider Selling: Artivion (NYSE:AORT) Insider Sells 4,573 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 4,573 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $172,767.94. Following the completion of the transaction, the insider owned 230,794 shares in the company, valued at $8,719,397.32. This represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Artivion Stock Performance

Artivion stock traded down $0.21 during midday trading on Wednesday, hitting $38.41. 460,494 shares of the company’s stock were exchanged, compared to its average volume of 509,518. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The firm’s 50 day simple moving average is $41.42 and its 200 day simple moving average is $42.92.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The company’s revenue was up 19.2% on a year-over-year basis. Equities research analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Institutional investors have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after buying an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Artivion in the third quarter valued at about $27,000. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas boosted its stake in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Oppenheimer reiterated an “outperform” rating and set a $50.00 price target on shares of Artivion in a research report on Friday, November 7th. Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Finally, Canaccord Genuity Group lowered their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.